$-0.97 EPS Expected for Flex Pharma, Inc. (FLKS)

February 15, 2018 - By Dolores Ford

 $ 0.97 EPS Expected for Flex Pharma, Inc. (FLKS)

Analysts expect Flex Pharma, Inc. (NASDAQ:FLKS) to report $-0.97 EPS on March, 14.They anticipate $0.49 EPS change or 102.08 % from last quarter’s $-0.48 EPS. After having $-0.54 EPS previously, Flex Pharma, Inc.’s analysts see 79.63 % EPS growth. The stock decreased 1.83% or $0.08 during the last trading session, reaching $4.3. About 33,715 shares traded. Flex Pharma, Inc. (NASDAQ:FLKS) has declined 70.24% since February 15, 2017 and is downtrending. It has underperformed by 86.94% the S&P500.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Coverage

Among 6 analysts covering Flex Pharma (NASDAQ:FLKS), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Flex Pharma had 8 analyst reports since August 21, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, August 3. Jefferies maintained the shares of FLKS in report on Tuesday, February 13 with “Buy” rating. Zacks downgraded the shares of FLKS in report on Friday, August 21 to “Hold” rating. The company was downgraded on Friday, October 14 by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, September 7 by Roth Capital. The stock of Flex Pharma, Inc. (NASDAQ:FLKS) earned “Hold” rating by Cantor Fitzgerald on Tuesday, July 25. As per Wednesday, September 2, the company rating was upgraded by Zacks.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $77.28 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.

More notable recent Flex Pharma, Inc. (NASDAQ:FLKS) news were published by: Businesswire.com which released: “Flex Pharma Names Dr. Roger Tung to Its Board of Directors” on October 31, 2017, also Businesswire.com with their article: “Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases” published on January 24, 2017, Bostonglobe.com published: “Flex Pharma chief executive steps down” on June 05, 2017. More interesting news about Flex Pharma, Inc. (NASDAQ:FLKS) were released by: Marketwatch.com and their article: “Flex Pharma Inc.” published on March 25, 2016 as well as Businesswire.com‘s news article titled: “Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of …” with publication date: November 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.